查詢結果分析
來源資料
相關文獻
- Interstitial Pneumonitis after Combination Therapy with Pegylated Interferon α-2b and Ribavirin for Chronic Hepatitis C
- 慢性C型肝炎之治療
- Interferon-α Therapy for Children with Chronic Hepatitis C
- Treatment of Chronic Myelocytic Leukemia by Allogeneic Bone Marrow Transplantation in Eleven Patients
- 慢性C型肝炎與肝癌關係
- 特發性間質性肺炎之分類與進展
- 臺灣肝臟病系列(40):慢性C型肝炎之抗病毒治療
- Expression of Interferon Alpha/Beta Receptor Genes in Peripheral Blood Cells of Chronic Hepatitis C Patients
- Probable Reinfection with Hepatitis C Virus in a Chronic Hepatitis C Patient with a Sustained Response to Combination Therapy
- Prolonged Interferon Treatment after Combination Interferon and Ribavirin Therapy in Patients with Chronic Hepatitis C: A Clinical Trial of Interferon Relapsers and Non-Responders
頁籤選單縮合
| 題 名 | Interstitial Pneumonitis after Combination Therapy with Pegylated Interferon α-2b and Ribavirin for Chronic Hepatitis C=慢性C型肝炎以pegylated干擾素α-2b及ribavirin治療後併發間質性肺炎 |
|---|---|
| 作 者 | 陳永哲; 盧勝男; 林孟志; | 書刊名 | 長庚醫學 |
| 卷 期 | 30:1 2007.01-02[民96.01-02] |
| 頁 次 | 頁92-97 |
| 分類號 | 415.5332 |
| 關鍵詞 | 間質性肺炎; 慢性C型肝炎; pegylated干擾素α-2b; Chronic hepatitis C; Pegylated interferon alpha-2b; Interstitial pneumonitis; |
| 語 文 | 英文(English) |
| 中文摘要 | 肺部毒性是以pegylated干擾素α-2b及ribavirin治療慢性C型肝炎時少見的副作用,我們報告一位47歲慢性C型肝炎的女性病患以pegylated干擾素α-2b及ribavirin治療後10週,得到良好的反應。然後,她開始出現用力時呼吸短促及乾咳,根據胸部X-光,高解析度電腦斷層攝影及支氣管肺泡沖洗液分析的結果,診斷為間質性肺炎。Pegylated干擾素α-2b比傳統的干擾素α-2b有較長的吸收和清除半衰期,但效力相當,雖然pegylated干擾素α的耐受性和傳統的干擾素α相當,但是以不適當高劑量的長效性pegylated干擾素α治療時可能較容易產生肺毒性,依據MEDLINE直到2004年的搜尋,我們相信這是第一個慢性C型肝炎以pegylated干擾素α-2b及ribavirin治療後產生間質性肺炎而能復原的病例。臨床醫師以pegylated干擾素α-2b及ribavirin治療慢性C型肝炎應對這種併發症有高度的警覺性。 |
| 英文摘要 | Pulmonary toxicity is a rare but potentially fatal side effect occurring during interferon (IFN) α treatment for chronic hepatitis C. We present a 47-year-old woman who had chronic hepatitis C and was treated with pegylated IFN α-2b in combination with ribavirin, with a good virological response by week 10 of therapy. Then the patient began to complain of dyspnea on exertion and a dry cough. A diagnosis of interstitial pneumonitis was made according to the results of chest X-rays, high resolution computed tomography and bronchoalveolar lavage analysis. Pegylated IFN α-2b has a longer absorption and elimination half-life than conventional IFN α-2b and a comparable potency to conventional IFN α-2b. Although the tolerability of pegylated IFN α is comparable to that of conventional IFN α, pulmonary toxicity may occur more frequently with long-acting pegylated IFN α therapy at an inappropriately high dose. Based on a MEDLINE search up to 2004, we believe that this is the first reported case of a patient recovering from interstitial pneumonitis associated with pegylated IFN α-2b for chronic hepatitis C. Physicians should keep in mind the possibility of this complication when treating chronic hepatitis C patients with pegylated IFN α-2b and ribavirin combinational therapy. |
本系統中英文摘要資訊取自各篇刊載內容。